Barclays
ITRM

Barclays’s Iterum Therapeutics ITRM Stock Holding History

Barclays’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-500
Closed -$885 – 5396
2024
Q4 		$885 Buy
+500
New +$784 ﹤0.01% 5144
2021
Q2 		– Sell
-3,333
Closed -$71K – 4967
2021
Q1 		$71K Buy
+3,333
New +$79.3K ﹤0.01% 4119
2020
Q4 		– Sell
-2,667
Closed -$42K – 5041
2020
Q3 		$42K Buy
+2,667
New +$35.6K ﹤0.01% 4684

Other funds holding ITRM

NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
AF
Apollon Financial Mount Pleasant, South Carolina $723M AUM 24.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
CFD
Creative Financial Designs Kokomo, Indiana $1.65B AUM 15.6% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $18.5B AUM 23.32% 1-Year Est. Return
LF
Lee Financial Dallas, Texas $709M AUM 18.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Barclays's ITRM Position: Q1 2025 in Review

Barclays sold out of Iterum Therapeutics (ITRM) in Q1 2025, closing a stake of 500 shares — an estimated $885 sold.

Barclays first reported a position in ITRM in Q3 2020 and held it in 3 quarters. The position peaked at $71K in Q1 2021. 20 funds tracked by Wall St. Rank hold ITRM as of Q1 2025.

  • Barclays reported no remaining Iterum Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Barclays sold 500 Iterum Therapeutics shares in Q1 2025, an estimated $885.
  • Barclays first reported a position in Iterum Therapeutics in Q3 2020 and held it in 3 quarters.
  • Barclays's Iterum Therapeutics position peaked at $71K in Q1 2021.
  • 20 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q1 2025.

Based on Barclays's 13F filing for Q1 2025, filed 15 May 2025.